Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25439439 | 0.86 | NAMPT (0.48) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL133327 | 0.82 | KMT2A (0.60) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL3180689 | 0.81 | L3MBTL1 (0.61) | NAMPTHDAC1L3MBTL1GAACTSK | |
| SCHEMBL8579767 | 0.81 | NAMPT (0.46) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL8220824 | 0.80 | EPHX2 (0.60) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL25337168 | 0.80 | KMT2A (0.45) | HDAC1EPHX2NR1H4HDAC6 | |
| SCHEMBL2874913 | 0.79 | NAMPT (0.54) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL8203403 | 0.79 | NAMPT (0.54) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL3274015 | 0.79 | EPHX2 (0.58) | NAMPTHDAC1L3MBTL1EPHX2GAA | |
| SCHEMBL10165179 | 0.79 | NAMPT (0.56) | NAMPTHDAC1L3MBTL1EPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4211117-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | Loxo Oncology, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116323553-A | Processes and intermediates for preparing (S) -5-amino-3- (4- ((5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (1, 1-trifluoropropan-2-yl) -1H-pyrazole-4-carboxamide | 罗索肿瘤学公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022056100-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | CYP4B1, PFAS, CYP2E1 | NAMPT 1167/4885HDAC1 747/4885L3MBTL1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.